Monthly Prescribing Reference

Adalimumab-adbm Injection, an Interchangeable Biosimilar to Humira, Now Available

Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...
Yahoo

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
Drug Store News

7 companies are rolling out Humira biosimilars

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...
JD Supra

What Do the Humira Biosimilar / Interchangeable Launches Mean for the Adalimumab Market?

At the beginning of July, seven additional Humira ® (adalimumab) biosimilars, including one interchangeable, joined Amjevita™ (adalimumab-atto) in the US marketplace. Abrilada™ (adalimumab-afzb) is ...
Fierce Healthcare

Evernorth's Accredo to offer Humira biosimilar at $0 out-of-pocket

Evernorth's Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs, the company announced Thursday. Accredo is the specialty pharmacy segment within Evernorth ...
Healio

Boehringer Ingelheim, Quallent partner to expand Humira biosimilar access

Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...
Healthline

Biosimilar Drugs to Humira Are Arriving: Why Prices Won't Be Significantly Lower

Share on Pinterest The drug Humira is used to treat several types of arthritis. Eclipse Images/Getty Images The patent has finally expired for Humira, the biologic drug used to treat arthritis, ...
JD Supra

Federal Court declines to grant injunction for infringement of HUMIRA formulation patent

On December 4, 2023, the Federal Court issued its public judgment and reasons in two patent infringement actions pursuant to s. 6(1) of the Patented Medicines (Notice of Compliance) Regulations ...
Nasdaq

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...
The Boston Globe

Low-cost versions of Humira, the nation’s top-selling drug, are off to a sluggish start

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...
SFGate

Abbott Sees '03 Humira Sales Over $150M

Abbott Laboratories, which received a surprisingly quick approval for its Humira rheumatoid-arthritis drug earlier this week, expects the drug to see sales of more than $150 million globally in 2003 ...